Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

iShares PHLX Semiconductor ETF / Technical Analysis

<ul>
<li>We remain bullish (as of our 4/21/26 Compass) on the S&amp;P 500 (SPX), and we will stay that way as long as support at 7507-7580 holds.</li>
<li>We continue to believe Technology and A.I. areas (XLK, SOXX, DRAM) are poised to move higher, and we have Technology on watch for a potential upgrade to overweight.</li>
<li>A significant "wall of worry" is being built, with the latest bricks being bad breadth and rising interest rate volatility</li>
</ul>


We remain bullish (as of our 4/21/26 Compass) on the S&amp;P 500 (SPX), and we will stay that way as long as support at 7507-7580 holds.
We continue to believe Technology and A.I. areas (XLK, SOXX, DRAM) are poised to move higher, and we have Technology on watch for a potential upgrade to overweight.
A significant "wall of worry" is being built, with the latest bricks being bad breadth and rising interest rate volatility


Interest Rate Volatility, High Yield Spreads, and Bad Breadth a Concern? All Hinges on 7507-7580 SPX

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Thermo Fisher Scientific Inc / Equity Bottom-Up

<ul><li>Thermo Fisher Scientific reported its second quarter of 2026 with notable financial and operational performance across its diverse business segments.</li><li>The company achieved a 10% increase in revenue to $11.99 billion, led by 5% organic growth, 5% contribution from recent acquisitions, and a minor foreign exchange tailwind.</li><li>Adjusted operating income expanded by 15% to $2.73 billion, supported by a 90 basis point increase in adjusted operating margin to 22.8%.</li></ul>

Thermo Fisher Scientific reported its second quarter of 2026 with notable financial and operational performance across its diverse business segments.The company achieved a 10% increase in revenue to $11.99 billion, led by 5% organic growth, 5% contribution from recent acquisitions, and a minor foreign exchange tailwind.Adjusted operating income expanded by 15% to $2.73 billion, supported by a 90 basis point increase in adjusted operating margin to 22.8%.

Thermo Fisher Scientific’s $1.6 Billion Acquisition Boost: Is Integration Paying Off?

Equity Long-Short Analyst

Pyari Menon

Thematic (Sector/Industry)

<ul>
<li>Innovation data suggests that <a href="https://www.smartkarma.com/entities/bayer-ag" target="_blank" data-smartkarma-citation="entities:26881:1" rel="noopener">Bayer AG (BAYN GY)</a> has an almost monopoly stake in agriculture-related microbial, followed by <a href="https://www.smartkarma.com/entities/dupont-de-nemours-inc" target="_blank" data-smartkarma-citation="entities:9239:1" rel="noopener">DuPont (DD US)</a> </li>
<li>In non-ag microbial space <a href="https://www.smartkarma.com/entities/moderna-inc" target="_blank" data-smartkarma-citation="entities:28744:1" rel="noopener">Moderna Inc (MRNA US)</a>,  <a href="https://www.smartkarma.com/entities/codexis-inc" target="_blank" data-smartkarma-citation="entities:26400:1" rel="noopener">Codexis Inc (CDXS US)</a>,  <a href="https://www.smartkarma.com/entities/regeneron-pharmaceuticals" target="_blank" data-smartkarma-citation="entities:9167:1" rel="noopener">Regeneron Pharmaceuticals (REGN US),</a><a href="https://www.smartkarma.com/entities/immatics-nv" target="_blank" data-smartkarma-citation="entities:33092:1" rel="noopener">Immatics NV (IMTX US)</a> lead the field</li>
<li>In the nascent area of bacteriophages which could be a game-changer to fight against antibiotic-resistant bacteria BOEHRINGER INGELHEIM, <a href="https://www.smartkarma.com/entities/johnson-johnson" target="_blank" data-smartkarma-citation="entities:1132:1" rel="noopener">Johnson &amp; Johnson (JNJ US)</a>, and <a href="https://www.smartkarma.com/entities/pfizer-inc" target="_blank" data-smartkarma-citation="entities:1131:1" rel="noopener">Pfizer Inc (PFE US) </a>lead</li>
</ul>


Innovation data suggests that Bayer AG (BAYN GY) has an almost monopoly stake in agriculture-related microbial, followed by DuPont (DD US) 
In non-ag microbial space Moderna Inc (MRNA US),  Codexis Inc (CDXS US),  Regeneron Pharmaceuticals (REGN US),Immatics NV (IMTX US) lead the field
In the nascent area of bacteriophages which could be a game-changer to fight against antibiotic-resistant bacteria BOEHRINGER INGELHEIM, Johnson &amp; Johnson (JNJ US), and Pfizer Inc (PFE US) lead


Insights from Data Mining Technical Publications - Microbes - Bacteriophages

<ul><li>Thermo Fisher Scientific reported a solid start to 2026, with first-quarter revenue rising 6% year-over-year to $11.01 billion and adjusted operating income also increasing 6% to $2.4 billion.</li><li>Adjusted earnings per share grew by 6% to $5.44, while the adjusted operating margin held steady near 21.8%.</li><li>These results led the company to raise its full-year guidance, now anticipating revenue between $47.3 billion and $48.1 billion and adjusted EPS in the range of $24.64 to $25.12, reflecting an 8% to 10% increase from 2025.</li></ul>

Thermo Fisher Scientific reported a solid start to 2026, with first-quarter revenue rising 6% year-over-year to $11.01 billion and adjusted operating income also increasing 6% to $2.4 billion.Adjusted earnings per share grew by 6% to $5.44, while the adjusted operating margin held steady near 21.8%.These results led the company to raise its full-year guidance, now anticipating revenue between $47.3 billion and $48.1 billion and adjusted EPS in the range of $24.64 to $25.12, reflecting an 8% to 10% increase from 2025.

Can Thermo Fisher Reduce 3.5x Leverage Before Tariff Headwinds Deepen In 2026?

Weekly podcast series by SemiWiki.com, SemiWiki.com

SemiWiki.com

Weekly podcast series by SemiWiki.com

Semiconductor Insiders: A weekly podcast series by SemiWiki.com, the open forum for semiconductor professionals.

Thermo Fisher Scientific  / Equity Bottom-Up

<ul>
<li>Thermo Fisher plays a critical role in helping customers in various industries find and fix defects, particularly in the semiconductor industry</li>
<li>The move towards 3D stacking architectures in semiconductor manufacturing offers benefits such as higher performance, lower power consumption, improved yield, and cost optimization</li>
<li>Increasing data center and AI workloads are pushing semiconductor manufacturers to utilize 3D analysis to detect chip defects earlier in order to maintain performance and efficiency</li>
</ul>
<p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.</em></p>


Thermo Fisher plays a critical role in helping customers in various industries find and fix defects, particularly in the semiconductor industry
The move towards 3D stacking architectures in semiconductor manufacturing offers benefits such as higher performance, lower power consumption, improved yield, and cost optimization
Increasing data center and AI workloads are pushing semiconductor manufacturers to utilize 3D analysis to detect chip defects earlier in order to maintain performance and efficiency

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.

Podcast EP338: How Thermo Fisher Scientific Helps Advanced Semiconductor Development

United States

Thermo Fisher Scientific, Inc. manufactures scientific instruments, consumables, and chemicals.  The Company offers analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals, and supplies to pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions, and government agencies.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Thermo Fisher Scientific Inc (TMO US)

Interest Rate Volatility, High Yield Spreads, and Bad Breadth a Concern? All Hinges on 7507-7580 SPX

Interest Rate Volatility, High Yield Spreads, and Bad Breadth a Concern?; All Hinges on 7507-7580 $SPX. We continue to believe Technology and A.I....

Vermilion Research

Thermo Fisher Scientific’s $1.6 Billion Acquisition Boost: Is Integration Paying Off?

Thermo Fisher Scientific reported its second quarter of 2026 with notable financial and operational performance across its diverse business...

Baptista Research

Insights from Data Mining Technical Publications - Microbes - Bacteriophages

Innovations are modifying and harnessing microbes for new uses in agriculture, industry, and as potential new therapeutics to replace or...

Pyari Menon

Can Thermo Fisher Reduce 3.5x Leverage Before Tariff Headwinds Deepen In 2026?

Thermo Fisher Scientific reported a solid start to 2026, with first-quarter revenue rising 6% year-over-year to $11.01 billion and adjusted...

Baptista Research

Podcast EP338: How Thermo Fisher Scientific Helps Advanced Semiconductor Development

Thermo Fisher's electron microscopes are critical tools for detecting defects in semiconductors, including 3D architectures, to protect yield and...

SemiWiki.com

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)